Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical
Further new data for the Biogen and Eisai drug BAN2401 appear to show it significantly reduces amyloid plaque and cognitive declines in Alzheimer's patients in a dose-dependent manner, but a lot of questions – and skepticism about the data – remain.
You may also be interested in...
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.